Status:
COMPLETED
Treatment of COVID-19 Post-acute Cognitive Impairment Sequelae With tDCS
Lead Sponsor:
University of Sao Paulo
Collaborating Sponsors:
Fundação de Amparo à Pesquisa do Estado de São Paulo
Conditions:
Cognitive Impairment
Post-Acute Sequelae of SARS-CoV-2 Infection
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
After almost 2 years of pandemic, the consequences of the post-COVID syndrome, or PASC (Post Acute-Sequelae of Sars-CoV-2), have become a major challenge in the management of affected patients, genera...
Detailed Description
As of August 1, 2021, novel coronavirus disease 2019 (COVID-19), an infection caused by Severe Acute Respiratory Syndrome (SARS-CoV-2), had infected over 200 million people and accounted for more than...
Eligibility Criteria
Inclusion
- Age from 18 to 70 years;
- Positive diagnosis (confirmed by RT-PCR nasal swab) of COVID-19 within the last 6 months in relation to the time of assessment;
- Mild to moderate COVID-19 disease (no hospital stay required);
- A score above 10 in the cognitive symptoms domain of the Post-COVID-19 Symptom Assessment Questionnaire;
- Clinical neuropsychological assessment/neurological examination indicating cognitive impairment after acute COVID illness.
Exclusion
- Contraindications to the use of tDCS (such as metal plates on the head);
- Severe acute COVID-19 illness;
- Less than 8 years of schooling;
- Presence of serious neurological conditions such as neurocognitive disorders, stroke, lacunar infarction, cerebral atrophy and others;
- Presence of serious psychiatric disorders, such as untreated mood disorders (including suicidal ideation), personality disorders, or psychotic disorders;
- Unstable clinical conditions;
- Use of medications (such as benzodiazepines and anticonvulsants) that can impair cognition;
- Presence of pathological neuroimaging findings (eg, acute or subacute lacunar or hemorrhagic stroke and others);
- Presence of a pacemaker, orthosis or prosthesis incompatible with the performance of magnetic resonance imaging;
- Claustrophobia.
Key Trial Info
Start Date :
June 30 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 30 2023
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05389592
Start Date
June 30 2022
End Date
March 30 2023
Last Update
August 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto de Psiquiatria
São Paulo, Brazil